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OBJECTIVES: To identify current treatment patterns of care for patients with meta-
static breast cancer (MBC), refractory to anthracyclines and taxanes, treated under the 
perspective of the Brazilian public health care system. METHODS: A cross-sectional 
study of patients from 4 public hospitals in south and southeast region of Brazil. All 
patients q18 years diagnosed with MBC who had progressed following treatment with 
an anthracycline and a taxane between 2003 and 2006, with at least 4 months of survival 
after metastatics disease were included. Data was collected from their medical charts. 
RESULTS: 217 patients with an average age of 52 years (25–80 years old) were included 
in the analysis. Among patients with HER2 testing (59%), 40% were HER-2 positive 
and among patients with hormone receptor testing (89%), 51% were hormone receptor 
positive. 85% of the patients had information regarding treatments received in their 
medical charts. The most frequent chemotherapy regimens prescribed following use of 
anthracycline and taxane (“ﬁrst line”) were capecitabine (52.7%), gemcitabine  cispla-
tin (17.4%), and tamoxifen (8.7%). Second line treatment was prescribed for 58% of 
patients: gemcitabine  cisplatin (23.4%), capecitabine (20.6%), vinorelbine (14.0%), 
tamoxifen (12.1%), paclitaxel (4.7%) and letrozol (4.7%). The median number of treat-
ment regimens was 2, with a range of 1 to 6. The average resources utilization 
per patient/year included 1.85 plain thorax x-rays, 0.57 thorax CTs, 1.06 abdominal 
ultra-sounds, 0.46 abdominal CTs and 0.86 bone scintigraphies. The average survival 
of patients after ﬁrst breast cancer diagnosis was 44.8 months (SD: 35.8; median: 32.0) 
and after ﬁrst diagnosis of metastasis was 22.4 months (SD: 20.0; median: 16.1). The 
average survival post progression to anthracyclines and taxanes was 12.7 months 
(SD: 12.4; median: 8.4). CONCLUSIONS: Within the Brazilian public health care 
system, the most frequently used ﬁrst and second line treatments, for MBC.
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OBJECTIVES: To estimate predicted 3-year total CVE rates (per 1000) in Hispanic 
patients with mixed dyslipidemia treated with fenoﬁbric acid and a statin compared to 
statin monotherapy. METHODS: A disease outcomes model was used to predict 3-year 
total CVE rates (per 1000) using baseline lipid, and lipid efﬁcacy, data of Hispanic 
patients with mixed dyslipidemia from a pooled analysis of three large, double-blind, 
Phase III, randomized controlled trials that evaluated the efﬁcacy and safety of fenoﬁbric 
acid 135 mg combined with low-dose statin (LDS) (simvastatin 20 mg, rosuvastatin 
10 mg, atorvastatin 20 mg) or moderate-dose statin (MDS) (simvastatin 40 mg, rosuv-
astatin 20 mg, atorvastatin 40 mg) compared to equivalent dose statin monotherapy. 
Risk for primary and secondary CVE including myocardial infarction (MI), angina 
pectoris, and stroke were based on published risk equations from the Framingham 
Heart Study. Additional risk attributable to elevated TG levels is estimated using hazard 
ratios from the Copenhagen Heart Study. RESULTS: Co-administration of fenoﬁbric 
acid and LDS or MDS was predicted to reduce 3-year total CVE rates by 37% (from 33 
to 21 per 1000) and 22% (from 31 to 24 per 1000) compared to LDS and MDS mono-
therapy, respectively. The majority of CVE were attributable to MI, followed by angina 
and stroke in all treatment groups. CONCLUSIONS: These data suggest that the co-
administration of fenoﬁbric acid and LDS or MDS may result in a 37% and 22% 
reduction in 3-year total CVE rates in Hispanic patients with mixed dyslipidemia.
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OBJECTIVES: To predict multiple OLV attainment rates (per 1000) with the co-
administration of fenoﬁbric acid and low-dose statin (LDS) or moderate-dose statin 
(MDS) compared to equivalent dose statin monotherapy in Hispanic patients with 
mixed dyslipidemia. METHODS: A dyslipidemia outcomes model was used to predict 
multiple OLV attainment rates (deﬁned as achieving any of 3 of 4 targets: total-C, 
LDL-C, HDL-C, or TG) among a cohort of 1000 Hispanic patients with mixed dys-
lipidemia. The model simulates baseline lipid values to reﬂect natural co-variation 
using data from the National Health and Nutrition Examination Survey (1999–2004), 
simulates post-treatment improvements to reﬂect the lipid efﬁcacy of each treatment 
comparator, and then compares post-treatment improvements to US guideline-based 
lipid targets (LDL-C  100 mg/dL, TG  150 mg/dL, total-C  200 mg/dL; HDL-C  
40 mg/dL). Baseline lipid and lipid efﬁcacy data for the Hispanic population were 
from a pooled analysis of three large, double-blind, Phase III, randomized controlled 
trials evaluating the efﬁcacy and safety of fenoﬁbric acid combined with LDS or MDS 
as compared to statin monotherapy at equivalent doses. RESULTS: Compared to 
statin monotherapy, co-administration of fenoﬁbric acid with LDS and MDS is pre-
dicted to increase multiple OLV attainment rates by 63% (546 to 890 per 1000) and 
18% (630 to 745 per 1000), respectively. Fenoﬁbric acid, when co-administered with 
a statin, is predicted to result in higher proportions of patients achieving individual 
TG and HDL-C target levels; while statin monotherapy treatment is predicted to result 
in higher proportions of patients achieving LDL-C targets. CONCLUSIONS: These 
data suggest that co-administration of fenoﬁbric acid and LDS or MDS may enable 
more patients to achieve multiple OLV compared to statin monotherapy in Hispanic 
patients with mixed dyslipidemia.
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OBJECTIVOS: Evaluar la relación entre los niveles de HDL-C y el riesgo de eventos 
cardiovasculares mayores (ECVM) como desenlace compuesto incluyendo infarto del 
miocardio, angina, accidente cerebrovascular, y revascularizacion coronaria. MET-
ODOLOGÍAS: Análisis de cohorte restrospectivo de paraclínicos registrados la base de 
datos Ingenix LabRx. Se incluyeron pacientes con edad q50 años y perﬁl lipidico com-
pleto (fecha índice) entre el 1 de enero de 2000 y el 31 de diciembre de 2003. Todos los 
sujetos fueron enrolados en los 6 meses, antes del perﬁl lipidico y 12 meses después, ter-
minando el seguimiento cuando se presentara un ECVM o terminara su plan de salud. 
Modelos de regressión Cox fueron utilizados para evaluar el riesgo de presenter ECVM, 
controlando por ECVM previos y otros factores de riesgo cardiovascular. Hazard ratios 
(HR) multifactoriales fueron ajustados para ECVM con base en las categorías de HDL-
C: 46–50 mg/dL, 40–45 mg/dL y  40 mg/dL versus HDL-C  50 mg/dL y HDL-C: 
36–40 mg/dL, 30–35 mg/dL y  30 mg/DL versus HDL-C  40 mg/dL en mujeres y 
hombres, respectivamente. RESULTADOS: Un total de 255,953 pacientes cumplieron 
los criterios de inclusión; la mayoria (52%) fueron mujeres. En general, el riesgo de un 
ECVM se incrementó con cada 5 mg/dL de disminución en los niveles de HDL-C. Entre 
las mujeres, el HR para cada categoría fue de: 1.24 (95% IC, 1.16 a 1.34), 1.32 (95% 
IC, 1.23 a 1.41), y 1.51 (95% IC, 1.40 a 1.64). Entre los hombres los HR fueron: 1.22 
(95% IC, 1.16 a 1.28), 1.33 (95% IC, 1.26 a 1.40), 1.57 (95% IC, 1.44 a 1.70). CON-
CLUSIONES: En esta cohorte de población general, la categoría de HDL-C más baja 
se asoció con un incremento en el riesgo de un ECVM de un 51% y 57% en mujeres 
y hombres, respectivamente, comparado con la categoría de HDL-C más alta.
PCV4
COST AND OUTCOME ANALYSIS COMPARING PTCA & CABG IN LOW 
AND HIGH RISK PATIENTS
Singh S1, Malhotra S2, Tiwari P3
1Natl Instt of Pharm Edu & Res (NIPER), SAS Nagar, SAS NAGAR, India, 2Fortis Heart and 
Multispeciality Centre, SAS Nagar, India, 3Natl Instt of Pharm Edu & Res (NIPER), SAS 
Nagar, SAS Nagar, India
OBJECTIVES: The study was conducted at a private tertiary care hospital with the 
objective of performing a cost and outcome analysis of low and high risk patients who 
had undergone PTCA (n  148; 58.96%) and CABG (n  103; 41.03%). METHODS: 
Parameters like length of stay, post surgical survival, post surgical complications, read-
missions were assessed. RESULTS: The average length of stay for low and high risk 
patients who had undergone PTCA was 3.61 and 3.87 days, respectively and in case of 
CABG it was 10.94 and 10.31 days, respectively. The readmissions for PTCA patients 
within 1 year was 34 (22.97%) and only 5 (4.85%) for CABG patients. The average 
cost for low and high risk patients in PTCA was INR2,30,000/- and INR2,87,000/- 
respectively, and INR2,00,000/- and INR2,30,000/- in case of CABG. The average cost 
for PTCA (readmissions) with a follow up of 1 year was INR4,22,000/-. The results 
showed that CABG had a higher beneﬁt-to-cost ratio (0.53) as compared to PTCA 
(0.21). PTCA was associated with shorter hospital stay and mortality (2.85%) when 
compared to CABG (7.84%). CONCLUSIONS: The differences between PTCA and 
CABG for both low and high risk patients in cost, survival rate and quality of life were 
matching but 1 year follow up showed that recurrent procedures were required in case 
of PTCA. The results of this limited study need to be extrapolated in a very cautious 
manner. A selected set of patients are recommended for PTCA who require coronary 
intervention and there are reports showing that PTCA had better survival than CABG 
in patients with single vessel coronary artery diseases (CAD); whereas, CABG produced 
better survival than did PTCA in patients with severe, triple vessel CAD.
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PROPHYLAXIS OF HEART TRANSPLANTATION REJECTION: 
FINANCIAL IMPACT ANALYSIS BY BRAZILIAN PUBLIC HEALTH CARE 
SYSTEM AND A REVIEW OF ECONOMIC EVALUATIONS STUDIES OF 
EVEROLIMUS, MMF (MYCOPHENOLATE MOFETIL) AND AZATHIOPRINE
Suzuki C1, Navarro J2, Prismich G1, Vincze G3, Machnicki G3
1Novartis Biociências S/A, São Paulo, Brazil, 2Novartis Farmacêutica S.A, São Paulo, Brazil, 
3Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To analyze the ﬁnancial impact of reimbursing everolimus, azathio-
prine and MMF in heart transplantation by Brazilian Ministry of Health. To review 
